Program Schedule

421
Activity of Tigecycline and Comparators Against Lower Respiratory Tract (LRT) Isolates of Enterobacteriaceae from North America and Europe: 2009-2013

Session: Poster Abstract Session: Surveillance of Antimicrobial Resistance
Thursday, October 9, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC

Background: Enterobacteriaceae play a significant role in LRT infections in at risk patients, especially in the healthcare associated environment. Treatment options are increasingly limited due to increased resistance to cephalosporins and other antimicrobials, thus warranting careful monitoring of resistance trends. The purpose of this study was to determine the in vitro activity of Tigecycline and other key antibiotics against LRT isolates of Enterobacteriaceae obtained from patients in North American and European hospitals.

Methods: From 2009-2013 8,361 Enterobacteriaceae from LRT specimens were obtained from geographically distributed sites as part of the multi-year Tigecycline Evaluation Surveillance Trial (TEST). MICs were determined by the local laboratory using supplied microdilution panels and interpreted according to CLSI guidelines.

áááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááááá

Results:

 

Percent Susceptible

2009

2010

2011

2012

2013

NAa

EUa

NA

EU

NA

EU

NA

EU

NA

EU

Drugá áááááán =

440

601

576

1472

537

1100

943

1683

390

619

Amikacin

98.0

97.5

97.9

97.4

98.3

95.8

98.3

98.5

98.7

99.0

Cefepime

92.7

91.4

93.6

90.0

92.0

86.9

93.4

88.5

90.8

90.6

Ceftriaxone

73.9

72.1

72.1

67.7

75.6

69.7

80.3

71.0

78.2

71.1

Levofloxacin

83.4

84.2

86.6

82.1

84.4

81.4

87.6

83.6

85.4

83.4

Meropenem

96.4

97.2

96.2

98.7

97.8

96.5

97.3

97.0

96.2

97.7

Pip-Tazob

83.4

80.4

85.2

78.9

83.6

79.3

86.2

83.1

88.2

85.0

Tigecycline

98.0

94.7

96.4

96.4

96.8

97.7

96.3

97.0

96.2

97.0

ááááááááááááááááááááááá aNA: North America, EU: Europe; Pip-Tazo =á piperacillin/tazobactam

Conclusion: Tigecycline, amikacin and meropenem consistently demonstrated the highest % susceptibility (> 95%) against LRT isolates of Enterobacteriaceae regardless of study year or geographic region. Ceftriaxone was less active against European isolates than against North American isolates overall irrespective of study year possibly due to extended-spectrum β-lactamase prevalence in Europe vs. North America. Levofloxacin susceptibility was stable in the mid-80% range over all years. Tigecycline is not indicated for lower respiratory tract infections caused by Enterobacteriaceae.


 

Daryl Hoban, PhD1, Samuel Bouchillon, MD1, Meredith Hackel, PhD, MPH1, Brian Johnson, BS1, Robert Badal, BS1, Jack Johnson, MS, MBA1, Stephen Hawser, PhD2 and Heidi Leister-Tebbe, BS3, (1)International Health Management Associates, Inc., Schaumburg, IL, (2)IHMA Europe SÓrl, Epalinges, Switzerland, (3)Pfizer Inc., Collegeville, PA

Disclosures:

D. Hoban, Pfizer: Independent Contractor, Consulting fee

S. Bouchillon, Pfizer: Independent Contractor, Consulting fee

M. Hackel, Pfizer: Independent Contractor, Consulting fee

B. Johnson, Pfizer: Independent Contractor, Consulting fee

R. Badal, Pfizer: Independent Contractor, Consulting fee

J. Johnson, Pfizer: Independent Contractor, Consulting fee

S. Hawser, Pfizer: Independent Contractor, Consulting fee

H. Leister-Tebbe, Pfizer: Employee, Salary

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek